RxDoctor Payments Data

Zachary Lagrue

Physician Assistant · Pittston, PANPI 1972269629

Payments from drug & device makers

$2,637in general payments, 2019–2025

Across 109 payments — averaging $24.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$808
  • Amgen$367
  • Boston Scientific$222
  • Boehringer Ingelheim$167
  • Bayer$140
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$134
  • plus $800 from 16 others

What the payments were for

  • Food & beverage$2,57398%
  • Education$652%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,637 in reported general payments places this provider in the 85th percentile of 6,643 physician assistant providers in Pennsylvania.

See all physician assistant providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$26,864
Medicare patients
469
Services billed
689

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban96$84,611
JardianceEmpagliflozin65$63,885
XareltoRivaroxaban67$48,526
EntrestoSacubitril/Valsartan40$41,402
Repatha PushtronexEvolocumab17$10,237
Repatha SureclickEvolocumab12$6,488
Metoprolol Succinate136$1,982
Rosuvastatin Calcium115$1,645
Atorvastatin Calcium129$1,523
Ezetimibe56$1,510
Ranolazine ErRanolazine12$991
Losartan Potassium61$816
Telmisartan21$768
Isosorbide Mononitrate ErIsosorbide Mononitrate28$510
Valsartan18$351

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$125$84,61196 claims
Boehringer IngelheimJardiance$167$63,88565 claims
Johnson & JohnsonXarelto$124$48,52667 claims
NovartisEntresto$64$41,40240 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,643 physician assistant providers in Pennsylvania.

Other physician assistant in Pittston

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →